$5.930
-0.040 (-0.67%)Zum Schluss
STLN im Vergleich zur Peergroup
In the context of the broader market, STLN competes directly with industry leaders such as GMRS and FLGT. With a market capitalization of $657.36M, it holds a significant position in the sector. When comparing efficiency, STLN's gross margin of N/A stands against GMRS's 85.68% and FLGT's 27.02%. Such benchmarking helps identify whether Starling Oncology, Inc. is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von STLN
The company has a P/E ratio of -17.80 and a forward P/E of 0, indicating no expected earnings growth. The price-to-sales ratio is 1.10, which is relatively low, but the overall financial metrics suggest instability.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.